We are live on ! Find out more
HOWL icon

Werewolf Therapeutics
HOWL

41 hedge funds and large institutions have $107M invested in Werewolf Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

109% more capital invested

Capital invested by funds: $51.1M → $107M (+$55.7M)

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

17% more funds holding

Funds holding: 35 → 41 (+6)

9.48% more ownership

Funds ownership: 66.97% → 76.46% (+9.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
41
Holders Change
+6
Holders Change %
+17.14%
% of All Funds
0.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
13
Reduced
7
Closed
4
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
+$21K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5.19M
2
PHS
PFM Health Sciences
California
+$2.32M
3
Bank of America
Bank of America
North Carolina
+$1.44M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$832K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$453K

Top Sellers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
-$1.13M
2
SSA
Schonfeld Strategic Advisors
New York
-$374K
3
Millennium Management
Millennium Management
New York
-$56.9K
4
BCM
Bridgeway Capital Management
Texas
-$26.6K
5
BlackRock
BlackRock
New York
-$12.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$23.7M – – –
MAM
2
MPM Asset Management
Massachusetts
$16.5M – – –
PHS
3
PFM Health Sciences
California
$13.4M +$2.32M +909,895 +36%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$11.7M +$5.19M +2,033,658 +203%
MB
5
MPM BioImpact
Massachusetts
$9.22M – – –
Bank of America
6
Bank of America
North Carolina
$8.09M +$1.44M +564,157 +37%
RCMNY
7
Rubric Capital Management (New York)
New York
$7.47M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$3.37M +$832K +325,787 +59%
SFM
9
Sphera Funds Management
Israel
$2.42M – – –
DF
10
DC Funds
Virginia
$2.27M – – –
Millennium Management
11
Millennium Management
New York
$1.72M -$56.9K -22,263 -5%
Alyeska Investment Group
12
Alyeska Investment Group
Illinois
$1.68M +$96.8K +37,897 +10%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$750K +$51.2K +20,058 +12%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$684K +$453K +177,300 New
Two Sigma Investments
15
Two Sigma Investments
New York
$566K +$375K +146,736 New
Renaissance Technologies
16
Renaissance Technologies
New York
$415K +$159K +62,306 +138%
BCM
17
Bridgeway Capital Management
Texas
$328K -$26.6K -10,425 -11%
State Street
18
State Street
Massachusetts
$322K +$83.5K +32,700 +64%
LCM
19
Laurion Capital Management
New York
$306K -$1.13M -443,687 -85%
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$303K – – –
BlackRock
21
BlackRock
New York
$279K -$12.5K -4,885 -6%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$243K +$12.2K +4,795 +8%
Edgewood Management
23
Edgewood Management
Connecticut
$193K – – –
Northern Trust
24
Northern Trust
Illinois
$192K +$60.2K +23,581 +90%
HSA
25
HBK Sorce Advisory
Pennsylvania
$102K – – –
1
2

HOWL Hedge Fund Activity: Q4 2023 in Review

41 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2023, worth a combined $107M — up 109% from $51.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new HOWL positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $5.19M. The largest seller was Laurion Capital Management, cutting an estimated $1.13M.

  • 41 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2023, up from 35 in Q3 2023.
  • Funds reported $107M of Werewolf Therapeutics stock for Q4 2023, up 109% quarter-over-quarter.
  • 10 funds opened new Werewolf Therapeutics positions in Q4 2023 and 4 closed out, a net change of +6 holders.
  • The largest Werewolf Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $5.19M added.
  • The largest Werewolf Therapeutics seller in Q4 2023 was Laurion Capital Management, an estimated $1.13M sold.

Based on aggregated 13F filings for Q4 2023.